tailieunhanh - Clinical characteristics and disease outcomes in ER+ breast cancer: A comparison between HER2+ patients treated with trastuzumab and HER2- patients

Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN